Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Realty stocks lead the rally
Wed, 19 Oct 11:30 am

Indian stock market indices traded firm over the last two hours of trade on the back of sustained buying activity across index heavyweights. Realty and banking stocks witnessed maximum buying interest.

The BSE-Sensex is up by 267 points, while the NSE-Nifty is up by 81 points. BSE Mid Cap and BSE Small Cap indices are up by 1.34% and 1.08% respectively. The rupee is trading at 49.12 to the US dollar.

Banking stocks are trading strong. Andhra Bank and Dena Bank are the biggest winners. According to a leading financial daily, India's largest lender State Bank of India (SBI) is planning to tie up with Macquarie Group to raise US$ 1.5 bn for its second fund to invest in infrastructure assets and companies in India. The first fund, SBI Macquarie Infrastructure Trust which closed in March has raised US$ 1.2 bn. Both the companies hope to complete the paperwork quickly and be ready for launch over the next two months, although given global uncertainty and weak investor appetite, the launch could get delayed and could happen only in the first quarter of 2012. Like the first fund, the second will invest in core infrastructure assets including roads, utilities, telecoms, ports, airports and companies servicing those sectors.

Pharma stocks are trading strong led by J B Chemicals and Ranbaxy. According to a leading financial daily, Lupin is planning to enter into two marketing alliances to market adult vaccines and enhance its market share in chronic diseases segment in India. The company wants to tie up with a multinational and a domestic company by March 2012 to market the products. Lupin had decided to move away from the acute therapy, anti infective segment because of the stronger growth potential of the lifestyle and chronic therapy segment in India. Apart from vaccines, Lupin is also searching for a partner to help market cardiovascular, diabetes, gynecology and respiratory drugs. This is a positive step by the company given that chronic therapy drugs enjoy higher sales and margins.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty stocks lead the rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.